SOURCE: Cannabis Science, Inc.

Cannabis Science, Inc.

July 16, 2015 08:19 ET

Cannabis Science Signs Research & Distribution Agreement for California and Announces Guidance for Its New Product Releases in California and International Cannabinoid Research Operations

COLORADO SPRINGS, CO--(Marketwired - Jul 16, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicine and related consulting, is pleased to announce guidance in regards to its State-by-State initiatives, including its new product releases.

On the forefront are the California new product releases. The Company has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program. As a result of this new agreement with CSRF the Cannabis Science Patient Access Center will be moved to the CSRF website as well.

Please visit:

http://cannabisscienceresearchfoundation.org

http://cannabisscienceresearchfoundation.org/research/product-research

http://pac.cannabisscienceresearchfoundation.org

CSRF will be responsible for all of the CBIS State-by-State initiatives followed by Colorado, Washington, and subsequent States as scheduled products become available for distribution. The much-anticipated California release includes new extract products that will be the first in line and scheduled for release next week in California. This first batch of extracts will be followed by the second batch consisting of pill type capsules for oral consumption. These initial products will be available in a variety of dosage strengths, and subsequent products will be released in succession throughout the State of California.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact Information

  • Cannabis Science, Inc.
    Mr. Raymond C. Dabney
    President & CEO, Co-Founder
    raymond@cannabisscience.com
    Tel: 1.888.889.0888
    Direct: 1.310.650.3788

    Cannabis Science, Inc.
    Mr. Robert Kane
    Director & CFO
    info@cannabisscience.com
    Tel: 1.888.889.0888

    Cannabis Science, Inc.
    Mr. Derwin A. Wallace
    Finance & Investor Relations
    info@cannabisscience.com
    Tel: 1.888.889.0888
    Direct: 1.404.500.4950